期刊文献+

结直肠癌KRAS突变与临床病理特征的关系 被引量:11

Correlation of KRAS mutations and clinicopathological parameters in colorectal carcinoma
下载PDF
导出
摘要 目的检测结直肠患者KRAS的突变情况,分析KRAS突变与临床病理特征的关系。方法应用蝎形探针扩增阻滞突变系统(ARMS)荧光定量PCR技术,检测结直肠癌患者KRAS第12和13位密码子的突变情况并分析其与临床病理特征的关系。结果 1 207例结直肠癌KRAS突变率为42.92%(518/1 207)。第12号密码子6种突变类型,其中G12D突变率16.32%(197/1 207);G12V突变率10.36%(125/1 207);G12C突变率3.31%(40/1 207);G12S突变率2.40%(29/1 207);G12A突变率1.74%(21/1 207);G12R突变率0.58%(7/1 207)。第13号密码子G13D突变率为9.69%(117/1 207)。还检测出8种同时存在两种突变类型及一种同时存在3种突变类型。女性患者KRAS突变率(46.21%)高于男性(40.46%,P<0.05)。KRAS在右半结肠突变率(46.45%)和直肠突变率(44.50%)均高于左半结肠(37.50%,P<0.05)。结论结直肠癌KRAS突变有多种类型,并且多种突变类型可同时存在。女性患者突变率高于男性患者,右半结肠和直肠突变率均高于左半结肠。 Objective To investigate mutation rate and types of KRAS in colorectal carcinoma,and to analyze the relationship between KRAS mutation and clinicopathological parameters in patients with colorectal carcinoma( CRC). Methods Scorpions Amplification Refractory Mutation System( ARMS) fluorescence quantitative PCR was performed to detect the mutations in codons 12 and 13 of KRAS and to correlate between clinicopathological characteristics and the presence of various KRAS mutations of colorectal carcinoma. Results KRAS mutations were identified in 518 patients( 42. 92%),including G12 D( 197 cases, 16. 32%),G12 V( 125 cases,10. 36%),G12 C( 40 cases,3. 31%),G12 S( 29 cases,2. 40%),G12 A( 21 cases,1. 74%),G12 R( 7 cases,0. 58%),13 D( 117 cases,9. 69%). Female patients had a higher KRAS mutation rate than male( 46. 21%,238/515 vs. 40. 46%,280/692, P 0. 05). KRAS mutation was significantly higher in right colon cancer( 46. 45%,131/282) and in rectal cancer( 44. 50%,255/573) than that in left colon cancer( 37. 50%,132/352)( P〈0. 05,P〈0. 05). Conclusions There are many types of KRAS mutations in colorectal cancer,and many mutation types exist simultaneously. The detection rate of KRAS mutation is higher in female CRC patients than in the males. The detection rate of KRAS mutation is significantly higher in right colon cancer and in rectal cancer than that in left colon cancer.
出处 《基础医学与临床》 CSCD 2018年第1期32-36,共5页 Basic and Clinical Medicine
基金 福建省自然科学基金(2015J01424) 福建省立医院院内优秀青年基金(2014074)
关键词 结直肠肿瘤 DNA突变分析 基因 RAS 聚合酶链反应 colorectal neoplasms DNA mutational analysis genes ras polymerase chain reaction
  • 相关文献

参考文献3

二级参考文献29

  • 1Jing Gao, Yan-Yan Li, Ping-Nai Sun, Lin Shen.Comparative analysis of dideoxy sequencing,the KRAS StripAssay and pyrosequencing for detection of KRAS mutation[J].World Journal of Gastroenterology,2010,16(38):4858-4864. 被引量:8
  • 2Nordlinger B, Guiguet M, Vaillant JC,et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Fran~aise de Chirurgie. Cancer, 1996,77 (7) :1254- 1262. 被引量:1
  • 3Karapetis CS, Khambata-Ford S, Jonker D J, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med, 2008, 359 ( 17 ) : 1757-1765. 被引量:1
  • 4Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic: colorectal cancer. J Clin Oncol, 2008, 26 (10) : 1626-1634. 被引量:1
  • 5Peeters M, Price TJ, Cervantes A, et al. Randomized phase IH study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol, 2010, 28(51 ) :4706-4713. 被引量:1
  • 6Bokemeyer C, Bondarenko I, Hartmann JT, et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first- line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol, 2011, 22(7) :1535-1546. 被引量:1
  • 7NCCN. Clinical practice guidelines in oncology: colon cancer. Version 3. 2012 [ EB/OL]. [ 2012-07-16 ]. http://www, necn. org/professionals/physician_gls/pdf/colon, pdf. 被引量:1
  • 8Der C J, Cooper GM. Altered gene products are associated with activation of cellular Kras genes in human lung and colon carcinomas. Cell, 1983, 32( 1 ) :201-208. 被引量:1
  • 9Gideon P, John J, Frech M, et al. Mutational and kinetic: analyses of the GTPase-activating protein (GAP)-p21 interaction: the C-terminal domain of GAP is not sufficient for full activity. Mol Cell Biol, 1992,12 (5) :2050-2056. 被引量:1
  • 10Rajagopalan H, Bardelli A, Lengauer C, et al. Tumorigenesis : RAF/RAS oncogenes and mismatch-repair status. Nature, 2002, 418(6901 ) :934. 被引量:1

共引文献57

同被引文献105

引证文献11

二级引证文献61

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部